Free Trial

CymaBay Therapeutics (CBAY) Short Interest Ratio & Short Volume

Notice: This company has been marked as potentially delisted and may not be actively trading.

CymaBay Therapeutics Short Interest Data

Current Short Interest
5,850,000 shares
Previous Short Interest
8,370,000 shares
Change Vs. Previous Month
-30.11%
Dollar Volume Sold Short
$188.31 million
Short Interest Ratio
1.6 Days to Cover
Last Record Date
February 29, 2024
Outstanding Shares
114,724,000 shares
Percentage of Shares Shorted
5.10%
Today's Trading Volume
73 shares
Average Trading Volume
4,113,430 shares
Today's Volume Vs. Average
0%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling CymaBay Therapeutics ?

Sign up to receive the latest short interest report for CymaBay Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

CBAY Short Interest Over Time

CBAY Days to Cover Over Time

CBAY Percentage of Float Shorted Over Time

CymaBay Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
2/29/20245,850,000 shares $188.31 million -30.1%N/A1.6 $32.19
2/15/20248,370,000 shares $269.51 million -10.0%N/A2.4 $32.20
1/31/20249,300,000 shares $218.64 million -7.7%N/A5.4 $23.51
1/15/202410,070,000 shares $239.26 million +2.4%N/A5.4 $23.76
12/31/20239,830,000 shares $232.18 million -11.0%N/A5.2 $23.62
12/15/202311,050,000 shares $243.43 million -8.8%N/A5.7 $22.03
11/30/202312,120,000 shares $231.86 million +1.8%N/A5.9 $19.13
11/15/202311,910,000 shares $214.38 million +9.1%N/A5.3 $18.00
10/31/202310,920,000 shares $178.87 million +4.0%N/A4.8 $16.38
10/15/202310,500,000 shares $141.54 million +24.0%N/A5 $13.48
9/30/20238,470,000 shares $126.29 million -8.2%N/A4.1 $14.91
9/15/20239,230,000 shares $152.48 million +3.0%N/A3.9 $16.52
8/31/20238,960,000 shares $123.20 million -21.1%N/A3.7 $13.75
8/15/202311,350,000 shares $145.85 million -0.7%N/A6 $12.85
7/31/202311,430,000 shares $149.16 million -1.0%N/A6.2 $13.05
7/15/202311,540,000 shares $133.75 million -4.6%N/A6.3 $11.59
6/30/202312,100,000 shares $132.50 million +23.5%N/A6.4 $10.95
6/15/20239,800,000 shares $82.42 million +2.7%N/A6 $8.41
5/31/20239,540,000 shares $85.67 million -5.8%N/A6.3 $8.98
5/15/202310,130,000 shares $105.35 million -8.5%N/A6 $10.40
4/30/202311,070,000 shares $119.11 million +7.3%N/A6.8 $10.76
4/15/202310,320,000 shares $91.95 million +6.9%N/A5.7 $8.91
3/31/20239,650,000 shares $84.15 million +26.1%N/A5.6 $8.72
3/15/20237,650,000 shares $69.39 million +54.9%N/A4.7 $9.07
2/28/20234,940,000 shares $39.52 million +11.8%N/A3.6 $8.00
2/15/20234,420,000 shares $35.23 million -0.2%N/A3.5 $7.97
1/31/20234,430,000 shares $37.17 million +17.2%N/A4.1 $8.39
1/15/20233,780,000 shares $24.61 million +1.9%N/A4.5 $6.51
12/30/20223,710,000 shares $23.26 million +7.9%N/A6.2 $6.27
12/15/20223,440,000 shares $14.76 million +11.7%N/A7.4 $4.29
11/30/20223,080,000 shares $10.41 million +5.8%N/A8.2 $3.38
11/15/20222,910,000 shares $10.68 million +60.8%N/A8.2 $3.67
10/31/20221,810,000 shares $6.30 million +4.0%3.1%4.9 $3.48
10/15/20221,740,000 shares $5.78 million +10.1%2.9%4.1 $3.32
9/30/20221,580,000 shares $5.53 million +19.7%2.7%3.2 $3.50
9/15/20221,320,000 shares $5.40 million -27.1%2.2%2 $4.09
8/31/20221,810,000 shares $6.41 million -9.1%3.1%2.5 $3.54
8/15/20221,990,000 shares $8.06 million -36.2%3.4%2.7 $4.05
7/31/20223,120,000 shares $9.77 million -10.9%5.3%3.8 $3.13
7/15/20223,500,000 shares $11.87 million +51.5%5.9%4.2 $3.39
Elon Musk’s PRIME is Set to Shock the World (Ad)

Must-See: Elon's New Invention is Absolutely Insane When you click here and see what Elon Musk’s new invention does…You will NOT believe it. But Elon just tested this in a real human… And the result was mind-blowing.

Click here for the full story…
6/30/20222,310,000 shares $6.81 million -31.0%3.9%3 $2.95
6/15/20223,350,000 shares $6.47 million +17.5%5.7%4.5 $1.93
5/31/20222,850,000 shares $5.59 million -5.0%N/A5 $1.96
5/15/20223,000,000 shares $5.40 million +33.3%N/A5.8 $1.80
4/30/20222,250,000 shares $5.11 million +0.9%N/A4.8 $2.27
4/15/20222,230,000 shares $6.91 million -11.2%N/A5 $3.10
3/31/20222,510,000 shares $7.81 million +10.6%N/A5.7 $3.11
3/15/20222,270,000 shares $6.74 million +26.8%N/A5.1 $2.97
2/28/20221,790,000 shares $5.69 million +0.6%N/A4.2 $3.18
2/15/20221,780,000 shares $5.70 million +19.5%N/A3.6 $3.20
1/31/20221,490,000 shares $4.44 million -11.3%N/A2.7 $2.98
1/15/20221,680,000 shares $5.29 million -4.0%N/A3.1 $3.15
12/31/20211,750,000 shares $5.92 million -12.5%N/A3.6 $3.38
12/15/20212,000,000 shares $6.68 million +12.4%N/A3.9 $3.34
11/30/20211,780,000 shares $5.89 million -9.2%N/A3.6 $3.31
11/15/20211,960,000 shares $8.41 million -7.6%N/A4.5 $4.29
10/29/20212,120,000 shares $8.27 million -0.9%3.3%5.5 $3.90
10/15/20212,140,000 shares $8.58 million -0.5%3.3%5.4 $4.01
9/30/20212,150,000 shares $7.85 million -17.6%3.3%5 $3.65
9/15/20212,610,000 shares $9.92 million -5.4%4.1%5.7 $3.80
8/31/20212,760,000 shares $10.93 million -4.5%4.3%5.4 $3.96
8/13/20212,890,000 shares $10.49 million -10.0%4.5%4.4 $3.63
7/30/20213,210,000 shares $12.65 million -46.0%5.0%4.6 $3.94
7/15/20215,940,000 shares $25.01 million -22.4%9.2%8 $4.21
6/30/20217,650,000 shares $33.35 million -5.7%11.9%9.8 $4.36
6/15/20218,110,000 shares $39.66 million -3.9%12.6%10.1 $4.89
5/28/20218,440,000 shares $35.70 million +1.7%13.1%10.5 $4.23
5/14/20218,300,000 shares $34.15 million -1.0%12.9%9.4 $4.12
4/30/20218,380,000 shares $38.72 million -1.5%13.2%8.1 $4.62
4/15/20218,510,000 shares $36.25 million -1.4%N/A0 $4.26
3/31/20218,630,000 shares $37.97 million -6.2%13.5%7.5 $4.40
3/15/20219,200,000 shares $45.91 million +10.3%14.5%7.1 $4.99
2/26/20218,340,000 shares $40.53 million +22.3%13.1%6.6 $4.86
2/12/20216,820,000 shares $41.06 million +32.2%10.7%5.7 $6.02
1/29/20215,160,000 shares $28.59 million +31.3%8.3%4.7 $5.54
1/15/20213,930,000 shares $24.41 million -10.9%6.3%3.8 $6.21
12/31/20204,410,000 shares $25.93 million +8.1%7.1%4.3 $5.88
12/15/20204,080,000 shares $29.34 million -3.6%6.6%3.7 $7.19
11/30/20204,230,000 shares $31.56 million -0.9%6.8%3.5 $7.46
11/15/20204,270,000 shares $35.01 million -6.8%6.9%3.2 $8.20
10/30/20204,580,000 shares $40.26 million -23.2%9.8%3.1 $8.79
10/15/20205,960,000 shares $46.25 million -6.0%12.7%2 $7.76
9/30/20206,340,000 shares $45.90 million +5.5%13.5%1.7 $7.24
9/15/20206,010,000 shares $39.00 million -5.4%11.8%1.7 $6.49
8/31/20206,350,000 shares $41.08 million -8.4%12.5%1.8 $6.47
8/14/20206,930,000 shares $40.68 million -29.4%13.6%1.9 $5.87
7/31/20209,810,000 shares $34.83 million +22.6%14.8%1.8 $3.55
7/15/20208,000,000 shares $26.64 million -1.0%12.1%2 $3.33
6/30/20208,080,000 shares $28.20 million -0.4%12.2%2.5 $3.49
6/15/20208,110,000 shares $31.87 million -8.7%12.3%2.4 $3.93
Elon Musk’s PRIME is Set to Shock the World (Ad)

Must-See: Elon's New Invention is Absolutely Insane When you click here and see what Elon Musk’s new invention does…You will NOT believe it. But Elon just tested this in a real human… And the result was mind-blowing.

Click here for the full story…
5/29/20208,880,000 shares $32.90 million +5.6%13.4%2.7 $3.71
5/15/20208,410,000 shares $34.06 million +7.0%12.7%2.5 $4.05
4/30/20207,860,000 shares $14.31 million -3.1%12.6%4.9 $1.82
4/15/20208,110,000 shares $13.54 million -5.0%13.1%5.6 $1.67
3/31/20208,540,000 shares $14.18 million -9.2%13.8%5.7 $1.66
3/13/20209,406,300 shares $15.90 million +1.9%15.2%4.9 $1.69
2/28/20209,230,000 shares $12.55 million -1.0%14.9%5.7 $1.36
2/14/20209,320,000 shares $15.19 million +21.5%15.1%3.9 $1.63
1/31/20207,670,000 shares $12.27 million +7.0%12.6%3.5 $1.60
1/15/20207,170,000 shares $11.11 million +0.1%11.7%3.3 $1.55
12/31/20197,160,000 shares $13.60 million No Change11.7%3.4 $1.90

CBAY Short Interest - Frequently Asked Questions

What is CymaBay Therapeutics' current short interest?

Short interest is the volume of CymaBay Therapeutics shares that have been sold short but have not yet been closed out or covered. As of February 29th, traders have sold 5,850,000 shares of CBAY short. Learn More on CymaBay Therapeutics' current short interest.

What is a good short interest ratio for CymaBay Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CBAY shares currently have a short interest ratio of 2.0. Learn More on CymaBay Therapeutics's short interest ratio.

Which institutional investors are shorting CymaBay Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of CymaBay Therapeutics: Walleye Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is CymaBay Therapeutics' short interest increasing or decreasing?

CymaBay Therapeutics saw a decline in short interest in February. As of February 29th, there was short interest totaling 5,850,000 shares, a decline of 30.1% from the previous total of 8,370,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does CymaBay Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to CymaBay Therapeutics: Axsome Therapeutics, Inc. (16.23%), Insmed Incorporated (5.74%), HUTCHMED (China) Limited (0.26%), Biohaven Ltd. (10.91%), Perrigo Company plc (2.54%), Ultragenyx Pharmaceutical Inc. (5.59%), Alkermes plc (7.62%), Prestige Consumer Healthcare Inc. (3.79%), Arrowhead Pharmaceuticals, Inc. (7.74%), IDEAYA Biosciences, Inc. (16.17%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.39 billion), General Motors ($3.88 billion), Super Micro Computer, Inc. ($3.51 billion), Charter Communications, Inc. ($3.22 billion), Occidental Petroleum Co. ($3.13 billion), Tractor Supply ($2.76 billion), Coinbase Global, Inc. ($2.63 billion), Suncor Energy Inc. ($2.48 billion), Moderna, Inc. ($2.04 billion), and Royal Caribbean Cruises Ltd. ($1.87 billion). View all of the most shorted stocks.

What does it mean to sell short CymaBay Therapeutics stock?

Short selling CBAY is an investing strategy that aims to generate trading profit from CymaBay Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against CymaBay Therapeutics?

A short squeeze for CymaBay Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CBAY, which in turn drives the price of the stock up even further.

How often is CymaBay Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CBAY, twice per month. The most recent reporting period available is February, 29 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:CBAY) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners